Premium
MRP3‐Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression
Author(s) -
Lozano Elisa,
Asensio Maitane,
PerezSilva Laura,
Banales Jesus M.,
Briz Oscar,
Marin Jose J.G.
Publication year - 2020
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.31088
Subject(s) - cancer research , cisplatin , gene silencing , gemcitabine , biology , pharmacology , cancer , chemotherapy , gene , genetics
Background and Aims A limitation for the treatment of unresectable cholangiocarcinoma (CCA) is its poor response to chemotherapy, which is partly due to reduction of intracellular levels of anticancer drugs through ATP‐binding cassette (ABC) pumps. Low expression of SOX17 (SRY‐box containing gene 17), a transcription factor that promotes biliary differentiation and phenotype maintenance, has been associated with cholangiocyte malignant transformation. Whether SOX17 is also involved in CCA chemoresistance is investigated in this study. Approach and Results SOX17 expression in human CCA cells (EGI‐1 and TFK‐1) selectively potentiated cytotoxicity of SN‐38, 5‐fluorouracil and mitoxantrone, but not that of gemcitabine, capecitabine, cisplatin, or oxaliplatin. The analysis of the resistome by TaqMan low‐density arrays revealed changes affecting primarily ABC pump expression. Single‐gene quantitative real‐time PCR, immunoblot, and immunofluorescence analyses confirmed that MRP3 (multidrug resistance associated protein 3), which was highly expressed in CCA human tumors, was down‐regulated in SOX17‐transduced CCA cells. The substrate specificity of this pump matched that of SOX17‐induced in vitro selective chemosensitization. Functional studies showed lower ability of SOX17‐expressing CCA cells to extrude specific MRP3 substrates. Reporter assay of MRP3 promoter ( ABCC3pr ) revealed that ABCC3pr activity was inhibited by SOX17 expression and SOX2/SOX9 silencing. The latter was highly expressed in CCA. Moreover, SOX2/9, but not SOX17, induced altered electrophoretic mobility of ABCC3pr , which was prevented by SOX17. The growth of CCA tumors subcutaneously implanted into immunodeficient mice was inhibited by 5‐fluorouracil. This effect was enhanced by co‐treatment with adenoviral vectors encoding SOX17. Conclusions SOX9/2/17 are involved in MRP3‐mediated CCA chemoresistance. Restored SOX17 expression, in addition to its tumor suppression effect, induces selective chemosensitization due to MRP3 down‐regulation and subsequent intracellular drug accumulation.